$GBT Global Blood Therapeutics announces expanded access protocol for Oxbryta. Global Blood Therapeutics announced that an expanded access protocol, or EAP, for Oxbryta, or voxelotor, in pediatric patients with sickle cell disease, or SCD, has been initiated and is currently enrolling. The EAP is designed to provide access to Oxbryta prior to approval for children ages 4 to 11 years with SCD in the United States who have no alternative treatment options and are ineligible to participate in clinical trials of Oxbryta.